IN THE CLAIMS:

1. (Currently amended) A composition comprising at least one bioadhesive, at least one immunological adjuvant, and at least one antigen, wherein said bioadhesive is a cross-linked derivative of poly(acrylic acid) and wherein said composition is adapted for intranasal delivery.

2. (Original) The composition of claim 1 wherein the antigen is present at about 0.1% to 40% (w/w) antigen to bioadhesive and the adjuvant is present at about 0.1% to 40% (w/w) adjuvant to bioadhesive.

3. (Currently amended) The composition of claim 1 wherein the ~~bioadhesive is a mucoadhesive selected from the group consisting of~~ cross-linked ~~derivatives~~ derivative of poly(acrylic acid) is carbopol. ~~, polyvinyl alcohol, polyvinyl pyrollidone, polysaccharides, hydroxypropyl methylcellulose, lectins, fimbrial proteins, and carboxymethylcellulose.~~

4. (Currently amended) The composition of ~~claim 3~~ claim 1 wherein the cross-linked derivative of poly(acrylic acid) is ~~selected from the group consisting of carbopol and~~ polycarbophil.

5. (Canceled)

6. (Canceled)

7. (Currently amended) The composition according to any of ~~claims 1-6~~ claims 1-4 wherein the immunological adjuvant is selected from the group consisting of alum, detoxified mutants of bacterial ADP-ribosylating toxins, oil-in-water emulsion formulations, and muramyl peptides.

8. (Original) The composition of claim 7 wherein the bacterial ADP-ribosylating toxin is selected from the group consisting of LT-MF59, MPL, LT-K63, LT-R72, and PT-K9/G129.

9. (Original) The composition of claim 1 wherein the selected antigen is a viral antigen.

10. (Original) The composition of claim 9 wherein the viral antigen is an influenza antigen.

11. (Original) The composition of claim 1 wherein the bioadhesive is provided as a microsphere.

12. (Original) The composition of claim 9 wherein the selected antigen is encapsulated within the microsphere.

13. (Original) The composition of claim 9 wherein the selected antigen is adsorbed to the microsphere.

14. (Original) A pharmaceutical composition comprising the composition of claim 1 and at least one pharmaceutically acceptable mucosal excipient.

15. (Withdrawn) A method of making a pharmaceutical composition comprising combining the composition of claim 1 and at least one pharmaceutically acceptable mucosal excipient.

16. (Withdrawn) A method of immunization comprising administering a therapeutically effective amount of the composition of claim 14 to a vertebrate subject.

17. (Currently amended) A method of generating an immune response against an antigen comprising intranasally administering the composition of claim 1 to a vertebrate subject.

18. (Currently amended) A method of generating an immune response against an antigen comprising intranasally administering the composition of claim 14 to a vertebrate subject.

19. (Currently amended) A method of treatment comprising intranasally administering the composition of claim 1 to a vertebrate subject.

20. (Currently amended) A method of treatment comprising intranasally administering the composition of claim 14 to a vertebrate subject.

21. (Currently amended) A method of enhancing an immunological response against an antigen comprising intranasally administering the composition of claim 1 to a vertebrate subject.

22. (Currently amended) A method of enhancing an immunological response against an antigen comprising intranasally administering the composition of claim 14 to a vertebrate subject.

23. (Canceled)

24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Withdrawn) A method of making a pharmaceutical composition comprising combining the composition of claim 7 and at least one pharmaceutically acceptable mucosal excipient.

29. (Currently amended) A method of generating an immune response against an antigen comprising intranasally administering the composition of claim 7 to a vertebrate subject.

30. (Currently amended) A method of treatment comprising intranasally administering the composition of claim 7 to a vertebrate subject.

31. (Currently amended) A method of enhancing an immunological response against an antigen comprising intranasally administering the composition of claim 7 to a vertebrate subject.

32. (Withdrawn) The composition of claim 7 wherein the selected antigen is a viral antigen.

33. (New) A composition comprising at least one bioadhesive, at least one immunological adjuvant comprising a detoxified mutant of bacterial ADP-ribosylating toxin, and at least one antigen.

34. (New) The composition of claim 33 wherein the antigen is present at about 0.1% to 40% (w/w) antigen to bioadhesive and the adjuvant is present at about 0.1% to 40% (w/w) adjuvant to bioadhesive.

35. (New) The composition of claim 33 wherein the bioadhesive is a mucoadhesive selected from the group consisting of polyvinyl alcohol, polyvinyl pyrollidone, hydroxypropyl methylcellulose, lectins, fimbrial proteins, and carboxymethylcellulose.

36. (New) The composition of claim 33 wherein the mucoadhesive is a cross-linked derivative of poly(acrylic acid).

37. (New) The composition of claim 36 wherein the poly(acrylic acid) is selected from the group consisting of carbopol and polycarbophil.

38. (New) The composition of claim 33 wherein the mucoadhesive is a polysaccharide.

39. (New) The composition of claim 38 wherein the polysaccharide is selected from the group consisting of alginate and chitosan.

40. (New) The composition of claim 33 wherein the bacterial ADP-ribosylating toxin is selected from the group consisting of LT-MF59, MPL, LT-K63, LT-R72, and PT-K9/G129.

41. (New) The composition of claim 33 wherein the selected antigen is a viral antigen.

42. (New) The composition of claim 33 wherein the viral antigen is an influenza antigen.

43. (New) A pharmaceutical composition comprising the composition of claim 33 and at least one pharmaceutically acceptable mucosal excipient.

44. (New) A method of generating or enhancing an immune response against an antigen comprising administering a therapeutically effective amount of the composition of claim 33 to a vertebrate subject.

45. (New) A method of generating or enhancing an immune response against an antigen comprising administering a therapeutically effective amount of the composition of claim 41 to a vertebrate subject.

46. (New) A method of generating or enhancing an immune response against an antigen comprising administering a therapeutically effective amount of the composition of claim 42 to a vertebrate subject.